These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16759612)

  • 21. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma.
    Witzig TE
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S91-5. PubMed ID: 11587375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.
    Tsai DE; Maillard I; Schuster SJ; Nasta SD; Porter DL; Klumpp TR; Goldenberg DM; Luger SM; Alavi A; Sharkey RM; Hartzell KB; Stadtmauer EA
    Clin Lymphoma; 2003 Jun; 4(1):56-9. PubMed ID: 12837157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whither Radioimmunotherapy: To Be or Not To Be?
    Green DJ; Press OW
    Cancer Res; 2017 May; 77(9):2191-2196. PubMed ID: 28428282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma.
    Ghobrial I; Witzig T
    Oncology (Williston Park); 2004 May; 18(5):623-30; discussion 633-4, 637-8, 640. PubMed ID: 15209190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy.
    Gokhale AS; Mayadev J; Pohlman B; Macklis RM
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):194-201. PubMed ID: 16111589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDG PET CT assessment of treatment response after yttrium-90 ibritumomab tiuxetan radioimmunotherapy.
    Joyce JM; Degirmenci B; Jacobs S; McCook B; Avril N
    Clin Nucl Med; 2005 Aug; 30(8):564-8. PubMed ID: 16024958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.
    Schilder R; Molina A; Bartlett N; Witzig T; Gordon L; Murray J; Spies S; Wang H; Wiseman G; White C
    Cancer Biother Radiopharm; 2004 Aug; 19(4):478-81. PubMed ID: 15453962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radioimmunotherapy for B-cell non-hodgkin lymphomas.
    Tomblyn M
    Cancer Control; 2012 Jul; 19(3):196-203. PubMed ID: 22710895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.
    Cheson BD; Leonard JP
    N Engl J Med; 2008 Aug; 359(6):613-26. PubMed ID: 18687642
    [No Abstract]   [Full Text] [Related]  

  • 30. [90Y-ibritumomab tiuxetan in patients with follicular lymphoma relapsing or refractory to rituximab].
    Aurer I; Huić D; Zuvić M; Sever-Prebilić M; Ajduković R; Radman I; Skare-Librenjak L; Ostojić-Kolonić S; Labar B
    Lijec Vjesn; 2006; 128(7-8):224-7. PubMed ID: 17087138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radioimmunotherapy for non-Hodgkin's lymphoma.
    Emmanouilides C
    Semin Oncol; 2003 Aug; 30(4):531-44. PubMed ID: 12939722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radioligand Therapy in Lymphoma: Past, Present, and Future.
    Almeida LS; Delgado Bolton RC; Heringer VC; de Souza Medina S; Etchebehere E
    PET Clin; 2024 Oct; 19(4):475-494. PubMed ID: 38969564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radioimmunotherapy of lymphoma.
    Kuzel TM; Rosen ST
    Cancer Treat Res; 1993; 68():1-12. PubMed ID: 8105845
    [No Abstract]   [Full Text] [Related]  

  • 34. [Hematological toxicity of radioimmunotherpy with 90Y Ibritumomab].
    Jurczak W; Szostek M; Jakóbczyk M; Staszczak AS; Zimowska-Curyło D; Giza A; Sobociński M; Hubalewska-Dydejczyk A; Skotnicki AB
    Przegl Lek; 2012; 69(3):107-14. PubMed ID: 22764652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ibritumomab tiuxetan (Zevalin) for non-Hodgkin's lymphoma.
    Med Lett Drugs Ther; 2002 Nov; 44(1144):101-2. PubMed ID: 12494494
    [No Abstract]   [Full Text] [Related]  

  • 36. Correlation of marrow dose estimates based on serial pretreatment radiopharmaceutical imaging and blood data with actual marrow toxicity in anti-CD20 yttrium-90 monoclonal antibody radioimmunotherapy of non-Hodgkin's B-cell lymphoma.
    Erwin WD; Spies SM; Kelly ME; Rao P; Eckersberg-Rhodes TE; Nannapaneni M; Groch MW
    Nucl Med Commun; 2001 Feb; 22(2):247-55. PubMed ID: 11258413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.
    England CG; Rui L; Cai W
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):517-532. PubMed ID: 27844106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radioimmunotherapy in allogeneic nonmyeloablative conditioning for B cell lymphoma: should we use it more often?
    Khouri IF
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):199-200. PubMed ID: 25528389
    [No Abstract]   [Full Text] [Related]  

  • 39. Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
    Gordon LI
    Semin Oncol; 2003 Dec; 30(6 Suppl 17):23-8. PubMed ID: 14710400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High dose radioimmunotherapy in relapsed B-cell lymphoma with I-131 rituximab.
    Becker W; Behr T
    Ann Hematol; 2001; 80 Suppl 3():B130-1. PubMed ID: 11757696
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.